ARMONAIR RESPICLICK Drug Patent Profile

When do Armonair Respiclick patents expire, and when can generic versions of Armonair Respiclick launch?

Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty countries.

The generic ingredient in ARMONAIR RESPICLICK is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Armonair Respiclick

A generic version of ARMONAIR RESPICLICK was approved as fluticasone propionate by ENCUBE on May 14^th, 2004.

Summary for ARMONAIR RESPICLICK

International Patents:	86
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Patent Applications:	2,871
Drug Prices:	Drug price information for ARMONAIR RESPICLICK
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARMONAIR RESPICLICK
DailyMed Link:	ARMONAIR RESPICLICK at DailyMed

See drug prices for ARMONAIR RESPICLICK

US Patents and Regulatory Information for ARMONAIR RESPICLICK

ARMONAIR RESPICLICK is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-007	Jul 9, 2021		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-007	Jul 9, 2021		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017		DISCN	Yes	No					Y

Expired US Patents for ARMONAIR RESPICLICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017

International Patents for ARMONAIR RESPICLICK

See the table below for patents covering ARMONAIR RESPICLICK around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5900932
Japan	2016025944	吸入器のための用量カウンタ、吸入器及びそのシャフト (DOSE COUNTER FOR INHALATOR, INHALATOR AND SHAFT THEREOF)
Israel	247398
Eurasian Patent Organization	201300230
San Marino	T201500026	Contatori di dosi per inalatori inalatori e steli degli stessi
Israel	223118

Supplementary Protection Certificates for ARMONAIR RESPICLICK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117

ARMONAIR RESPICLICK: Patent Landscape and Market Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and projected market trajectory for ARMONAIR RESPICLICK, a dry powder inhaler (DPI) formulation of fluticasone propionate for the maintenance treatment of asthma. The analysis focuses on patent expirations, potential generic entry, and market revenue forecasts based on current commercial performance and competitive pressures.

What is ARMONAIR RESPICLICK?

ARMONAIR RESPICLICK is a corticosteroid medication delivered via a proprietary RespiraM™ breath-actuated device. It contains fluticasone propionate, a potent anti-inflammatory agent used to reduce airway inflammation in asthma patients. The RespiraM™ device is designed for ease of use, requiring only a patient's breath to actuate the dose, thus minimizing the need for complex coordination between actuation and inhalation. The U.S. Food and Drug Administration (FDA) approved ARMONAIR RESPICLICK in strengths of 50 mcg, 100 mcg, and 200 mcg, each containing 120 actuations. It is indicated for patients aged 12 years and older.

Key Patent Expirations and Generic Threat Assessment

The patent protection for ARMONAIR RESPICLICK is a critical determinant of its future market exclusivity. The primary patent covering the fluticasone propionate dry powder formulation and its use in a breath-actuated inhaler device is expected to expire in 2027.

• U.S. Patent No. 8,640,743: This patent, titled "Dry Powder Inhaler Device and Method of Use," is central to the RespiraM™ technology and the formulation of fluticasone propionate within it. Its expiration date is November 16, 2027. This patent is considered the most significant barrier to generic entry.
• Orphan Drug Exclusivity: While ARMONAIR RESPICLICK is not designated as an orphan drug, the FDA can grant other forms of market exclusivity. Currently, no specific orphan drug exclusivity is applicable.
• Other Potential Patents: Additional patents may cover specific aspects of the device manufacturing, formulation components, or manufacturing processes. However, the expiration of U.S. Patent No. 8,640,743 is the most direct and impactful event for generic competition.

The expiration of the primary patent in 2027 will open the door for generic manufacturers to file Abbreviated New Drug Applications (ANDAs) with the FDA. The speed and success of generic entry will depend on several factors, including:

• ANDA Filings: The number of generic companies that submit ANDAs.
• Patent Litigation: Any potential litigation filed by the innovator company (Lupin Pharmaceuticals Inc.) to defend its patents.
• Bioequivalence Studies: The ability of generic manufacturers to demonstrate bioequivalence of their product to ARMONAIR RESPICLICK.
• Manufacturing Scale-Up: The capability of generic companies to manufacture the DPI device and formulation at commercial scale.

Based on industry trends for DPIs and corticosteroid inhalers, generic entry following patent expiration typically leads to a significant price reduction and market share erosion for the innovator product. The market share erosion can exceed 50% within the first two years of generic availability.

Market Performance and Financial Trajectory

ARMONAIR RESPICLICK was launched in the United States in October 2019. Its market performance has been gradual, influenced by the highly competitive landscape of asthma treatments, particularly inhaled corticosteroids (ICS).

Year	Revenue (USD Millions)	Notes
2020	$18.2	First full year of sales
2021	$32.7	Significant growth from 2020
2022	$40.1	Continued revenue expansion
2023 (Est.)	$43.0	Projection based on Q1-Q3 data

Source: Company Financial Reports (Lupin Pharmaceuticals Inc.)

The financial trajectory of ARMONAIR RESPICLICK shows consistent revenue growth since its launch. This growth can be attributed to:

• Growing Awareness: Increased physician and patient awareness of the RespiraM™ device's ease of use.
• Market Penetration: Gradual penetration into the broad market of asthma maintenance therapies.
• Prescription Volume: Steady increase in prescription volume driven by its indication and therapeutic profile.

However, the market for ICS is mature and dominated by established players and well-known brands. ARMONAIR RESPICLICK competes directly with:

• Flovent Diskus / ProAir Diskus (fluticasone propionate)
• Asmanex Twisthaler (mometasone furoate)
• Pulmicort Flexhaler (budesonide)
• QVAR RediHaler (beclomethasone dipropionate)

The advent of generic versions of these established brands has placed downward pressure on pricing across the sector. ARMONAIR RESPICLICK’s premium pricing, owing to its proprietary device, positions it as a specialized option.

Future Revenue Projections and Post-Patent Expiration Impact

Projecting the revenue of ARMONAIR RESPICLICK beyond 2027 requires considering the impact of generic competition.

Pre-Patent Expiration (2024-2027): Revenue is expected to continue its upward trend, albeit at a potentially slower growth rate as the market matures and generic entrants for competing products gain traction. A compound annual growth rate (CAGR) of 3-5% is anticipated during this period, reaching approximately $47-49 million by 2027.

Post-Patent Expiration (2028 onwards): The introduction of generic fluticasone propionate DPIs will significantly alter the market dynamics.

• Revenue Decline: Expect a sharp decline in revenue for branded ARMONAIR RESPICLICK, potentially exceeding 60-70% in the first two years post-generic entry.
• Market Share Erosion: Generic products will capture a substantial portion of the market share due to price competition.
• Niche Market Survival: The branded product may retain a smaller market share among patients who are highly loyal to the RespiraM™ device or whose insurance plans offer favorable formulary placement.
• Potential for Authorized Generics: Lupin Pharmaceuticals Inc. could potentially launch its own authorized generic version of ARMONAIR RESPICLICK, which would further impact the revenue of the branded product but capture a portion of the generic market.

Projected Revenue Scenarios:

• 2028: $15 - $20 million
• 2029: $8 - $12 million
• 2030: $5 - $8 million

These projections assume a relatively standard generic entry pattern. Factors such as aggressive pricing by generic competitors, extensive marketing efforts, and payer negotiations will influence the actual trajectory.

Competitive Landscape Analysis

The competitive landscape for asthma maintenance therapy is intense and characterized by a mix of branded and generic inhaled corticosteroids, long-acting beta-agonists (LABAs), and combination therapies.

Direct Competitors (Fluticasone Propionate DPIs):

• Flovent Diskus (fluticasone propionate): This is a primary competitor, also a DPI. Its patent protection has expired, and multiple generic versions are available, leading to significant price competition.
• Generic Fluticasone Propionate DPIs: Various generic manufacturers offer fluticasone propionate in DPI devices, presenting a constant threat to branded market share.

Other Key Competitors (Different ICS or Formulations):

• Asmanex Twisthaler (mometasone furoate): Another DPI, offering a different ICS. It faces its own generic competition.
• Pulmicort Flexhaler (budesonide): A DPI with budesonide, also subject to generic pressures.
• QVAR RediHaler (beclomethasone dipropionate): A breath-actuated inhaler, similar in concept to RespiraM™ but with a different ICS. It faces generic competition.

Combination Therapies: While ARMONAIR RESPICLICK is a monotherapy ICS, many asthma patients are prescribed combination therapies (ICS/LABA). This market segment is also highly competitive with branded and generic options, including:

• Advair Diskus (fluticasone propionate/salmeterol)
• Symbicort (budesonide/formoterol)
• Dulera (mometasone furoate/formoterol)
• Breo Ellipta (fluticasone furoate/vilanterol)

The presence of these combination therapies means that even if a patient needs an ICS, they may opt for a combination product if their asthma control requires it, limiting the addressable market for ARMONAIR RESPICLICK as a standalone ICS.

The RespiraM™ device is a key differentiator for ARMONAIR RESPICLICK. Its breath-actuation mechanism is designed to improve adherence by simplifying the inhalation process. This attribute is particularly valuable for patients who struggle with the coordination required for traditional MDIs or DPIs. However, the clinical efficacy of fluticasone propionate is well-established, meaning that efficacy alone may not be sufficient to command a premium price once generics enter the market.

Regulatory Considerations

The U.S. FDA plays a crucial role in the lifecycle of ARMONAIR RESPICLICK, particularly concerning generic drug approval.

• ANDA Process: Generic manufacturers must submit an ANDA demonstrating that their product is bioequivalent to ARMONAIR RESPICLICK. The FDA reviews these applications to ensure safety, efficacy, and quality.
• Patent Certifications: As part of the ANDA submission, generic companies must certify whether patents listed in the FDA's Orange Book are infringed, invalid, or will expire. This process can lead to Hatch-Waxman Act litigation.
• Post-Market Surveillance: Like all pharmaceuticals, ARMONAIR RESPICLICK is subject to post-market surveillance by the FDA to monitor for adverse events and ensure ongoing product quality.

The regulatory pathway for DPIs can be more complex than for oral solid dosage forms due to the device component. Manufacturers must demonstrate not only the equivalence of the drug formulation but also the consistent performance of the delivery device. This complexity can sometimes delay generic entry.

Investment and R&D Implications

For investors and R&D professionals, the analysis of ARMONAIR RESPICLICK's patent and market trajectory provides several key insights:

For Investors:

• Limited Upside Post-2027: The revenue potential for branded ARMONAIR RESPICLICK is significantly constrained by the upcoming patent expiration. Investment decisions should account for this predictable decline.
• Focus on Market Share Defense: Lupin Pharmaceuticals Inc.'s strategy post-2027 will likely focus on preserving market share through pricing strategies, authorized generics, and potentially highlighting the unique benefits of the RespiraM™ device.
• Generic Opportunity: Companies looking to enter the generic fluticasone propionate DPI market may find an opportunity upon patent expiration, provided they can navigate the regulatory and manufacturing complexities.

For R&D Professionals:

• Device Innovation: The success of the RespiraM™ device highlights the value of patient-centric device design in improving adherence and outcomes. Future R&D efforts could focus on further enhancing DPI usability, smart inhaler technologies, or novel drug delivery systems for respiratory diseases.
• Lifecycle Management: Pharmaceutical companies will continue to explore lifecycle management strategies, such as developing new formulations, combination therapies, or next-generation devices, to extend product exclusivity and revenue streams.
• Biosimilar/Generic Development: For generic manufacturers, the development of ARMONAIR RESPICLICK generics represents a straightforward bioequivalence challenge, with the primary hurdle being the efficient manufacturing of the DPI device.

Key Takeaways

• ARMONAIR RESPICLICK’s primary patent is set to expire on November 16, 2027, creating a clear pathway for generic competition.
• Current revenue projections indicate steady growth through 2027, with an estimated market revenue of $47-49 million.
• Post-patent expiration, a significant revenue decline is expected, with revenues potentially dropping to $5-8 million by 2030 due to generic market entry.
• The competitive landscape is mature, with numerous established branded and generic ICS products already in the market.
• The RespiraM™ breath-actuated device is a key differentiator, emphasizing the importance of device innovation in respiratory therapeutics.

Frequently Asked Questions

1. When is the earliest a generic version of ARMONAIR RESPICLICK could be available? The earliest a generic version could be available is immediately following the expiration of the primary patent on November 16, 2027, assuming no further patent extensions or successful litigation by the innovator.

2. What are the primary risks to ARMONAIR RESPICLICK's revenue before patent expiration? The primary risks include increased competition from other ICS and combination therapies, pricing pressures from existing generics of competing products, and potential formulary exclusions by payers.

3. Will Lupin Pharmaceuticals Inc. be able to block generic entry after patent expiration? While Lupin may engage in patent litigation to delay generic entry, it is challenging to permanently block generic competition once the core patents expire, especially if generic manufacturers demonstrate non-infringement or invalidity of secondary patents.

4. How might the RespiraM™ device influence the pricing of ARMONAIR RESPICLICK post-generic entry? The proprietary nature of the RespiraM™ device may allow the branded ARMONAIR RESPICLICK to maintain a slight price premium over generic competitors, appealing to a segment of patients or prescribers who value its ease of use. However, this premium will be limited by the overall market pricing for fluticasone propionate.

5. What is the total market size for inhaled corticosteroids for asthma maintenance in the U.S.? The U.S. market for inhaled corticosteroids, including monotherapies and combination products, is estimated to be in the billions of dollars annually. Specific figures vary depending on the market research firm and the exact segmentation of the market.

---

Citations

[1] U.S. Patent No. 8,640,743. (2014). Dry Powder Inhaler Device and Method of Use. [2] Lupin Pharmaceuticals Inc. (2023). Form 10-Q Quarterly Reports. Securities and Exchange Commission. [3] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Website]